Pharmaceuticals & Biotechnology
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Technicals: Bullish SharesGuru indicator.
Size: It is a small market cap company and can be volatile.
Momentum: Stock has a weak negative price momentum.
Growth: Declining Revenues! Trailing 12m revenue has fallen by -17.9% in past one year. In past three years, revenues have changed by -5.6%.
Smart Money: Smart money looks to be reducing their stake in the stock.
Past Returns: Underperforming stock! In past three years, the stock has provided -56.1% return compared to 12.2% by NIFTY 50.
Valuation | |
|---|---|
| Market Cap | 947.28 Cr |
| Price/Earnings (Trailing) | -35.25 |
| Price/Sales (Trailing) | 2.72 |
| EV/EBITDA | -300.9 |
| Price/Free Cashflow | 60.18 |
| MarketCap/EBT | -39.29 |
| Enterprise Value | 1.03 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 348.07 Cr |
| Rev. Growth (Yr) | -31.2% |
| Earnings (TTM) | -26.98 Cr |
| Earnings Growth (Yr) | -125.3% |
Profitability | |
|---|---|
| Operating Margin | -7% |
| EBT Margin | -7% |
| Return on Equity | -7.1% |
| Return on Assets | -4.63% |
| Free Cashflow Yield | 1.66% |
Growth & Returns | |
|---|---|
| Price Change 1W | 1.7% |
| Price Change 1M | -2.3% |
| Price Change 6M | -20.6% |
| Price Change 1Y | -60.7% |
| 3Y Cumulative Return | -56.1% |
| 5Y Cumulative Return | -22.1% |
| 7Y Cumulative Return | -16% |
| 10Y Cumulative Return | -15% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -12.17 Cr |
| Cash Flow from Operations (TTM) | 34.71 Cr |
| Cash Flow from Financing (TTM) | -25.9 Cr |
| Cash & Equivalents | 8.13 Cr |
| Free Cash Flow (TTM) | 19.28 Cr |
| Free Cash Flow/Share (TTM) | 2.1 |
Balance Sheet | |
|---|---|
| Total Assets | 582.5 Cr |
| Total Liabilities | 202.49 Cr |
| Shareholder Equity | 380.01 Cr |
| Current Assets | 299 Cr |
| Current Liabilities | 173.92 Cr |
| Net PPE | 168.69 Cr |
| Inventory | 76.45 Cr |
| Goodwill | 0.00 |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.16 |
| Debt/Equity | 0.25 |
| Interest Coverage | -3.3 |
| Interest/Cashflow Ops | 4.42 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 0.5 |
| Dividend Yield | 0.49% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Summary of Themis Medicare's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Last updated:
Last updated:
Understand Themis Medicare ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Vividhmargi Investments Pvt Ltd | 15.78% |
| Gedeon Richter Investment Management Ltd. | 9.61% |
| Dinesh Shantilal Patel | 9.47% |
| Vividh Distributors Pvt Ltd | 7.78% |
| Jayshree D Patel | 7.25% |
| Sachin Dinesh Patel | 5.99% |
| Anuj Anantrai Sheth | 4.09% |
| Reena S Patel | 4.04% |
| Themis Distributors Private Limited | 2.98% |
| Zafar Ahmadullah | 2.11% |
| Za Capital Services India Private Ltd | 1.53% |
| Anay Rupen Choksi | 1.28% |
| Nysha Rupen Choksi | 1.28% |
| Dinesh S Patel Huf | 1.07% |
| Shantilal Dahyabhai Patel (HUF) | 0.61% |
| Rupen Ashwin Choksi | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Themis Medicare against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| JUBLPHARMA | JUBILANT PHARMOVA | 16.99 kCr | 7.66 kCr | -0.90% | -2.80% | 35.36 | 2.22 | - | - |
| GRANULES | Granules India | 14.86 kCr | 4.87 kCr | +14.90% | +2.60% | 28.97 | 3.05 | - | - |
| STAR | STRIDES PHARMA SCIENCE | 8.63 kCr | 4.74 kCr | +5.20% | +36.00% | 21.7 | 1.82 | - | - |
| MARKSANS | Marksans Pharma | 8.25 kCr | 2.15 kCr | -3.60% | -38.00% | 23.43 | 3.84 | - | - |
| INDOCO | Indoco Remedies | 2.15 kCr | 1.73 kCr | -7.70% | -29.50% | -18.67 | 1.25 | - | - |
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. The company offers active pharmaceutical ingredients (APIs) and formulations for use in various therapeutic areas, including anti-tuberculosis, anti-malarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition, anaesthesia, gynecology, and orthopedics. It also offers anti-inflammatory drugs and other drugs. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is headquartered in Mumbai, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.